TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of “Moderate Buy” by Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has received a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $40.67.

Several research analysts recently commented on the stock. HC Wainwright lifted their target price on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. raised their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. TD Cowen initiated coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target for the company. Finally, StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 7th.

Insider Transactions at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now directly owns 100,195 shares of the company’s stock, valued at $3,049,935.80. The trade was a 4.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 26,358 shares of company stock valued at $781,497. Corporate insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. NBC Securities Inc. raised its holdings in TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 485 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 849 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in shares of TG Therapeutics in the second quarter worth $35,000. ORG Wealth Partners LLC bought a new position in shares of TG Therapeutics during the third quarter valued at $53,000. Finally, Values First Advisors Inc. purchased a new stake in shares of TG Therapeutics during the third quarter valued at $58,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Stock Down 4.2 %

Shares of NASDAQ:TGTX opened at $27.67 on Tuesday. The stock has a market capitalization of $4.31 billion, a P/E ratio of -276.67 and a beta of 2.24. The stock’s 50-day moving average price is $31.55 and its 200-day moving average price is $25.52. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics has a 12-month low of $12.84 and a 12-month high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. During the same quarter in the previous year, the business earned $0.73 earnings per share. TG Therapeutics’s revenue was down 49.4% compared to the same quarter last year. On average, equities analysts anticipate that TG Therapeutics will post 0.17 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.